CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
提高 CAR-T 疗法治疗急性髓系白血病疗效的策略开发
英文原题：Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.
查看英文原题
Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
急性髓系白血病（AML）是一种致死性血液恶性肿瘤。随着免疫疗法、特别是CAR-T 细胞技术的发展，AML治疗发生了重大变化。尽管CAR-T 具有优势，用于治疗AML仍面临多项局限和挑战。寻找新靶点、改造CAR结构以提高疗效并降低副作用，以及采用双靶点CAR和逻辑线路，都是解决这些问题的典型关键策略。基因编辑技术进步后，通过编辑肿瘤细胞或正常细胞以产生治疗效果也日益受到关注。此外，联合多种药物已成为应对CAR-T 治疗部分障碍和困难的常用方法。本文主要总结近年来CAR-T 治疗AML的策略和进展。
展开英文摘要原文
Acute myeloid leukemia (AML) is a fatal blood malignancy. With the development of immunotherapy, particularly chimeric antigen receptor T cells (CAR-T), the treatment of AML has undergone a significant change. Despite its advantages, CAR-T still faces a number of limitations and challenges while treating AML.
Finding novel targets, altering the structure of CAR to increase efficacy while lowering side effects, and using double-target CAR and logic circuits are typical examples of key to answer these problems. With the advancement of gene editing technology, gene editing of tumor cells or normal cells to create therapeutic effects has grown in popularity.
Additionally, the combination of multiple drugs is routinely used to address some of the obstacles and difficulties associated with CAR-T therapy. The review's primary goal was to summarize recent strategies and developments of CAR-T therapy for AML.
论文信息
- 作者
- Guo S、Gao X、Sadhana M、Guo R、Liu J、Lu W、Zhao MF
- 第一作者单位
- First Center, Clinic College of Tianjin Medical University, Tianjin, 300192, China.China
- 通讯作者单位
- Department of Hematology, Tianjin First Central Hospital, Tianjin, 300192, China. mingfengzhao@sina.com.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Current treatment options in oncology2023 Nov
- 原文标识
- PubMed 37870695 · DOI 10.1007/s11864-023-01140-w